投资工具 / 美股
Boston Scientific · BSX
数据仅供参考,不构成投资建议。
投资工具 / 美股
数据仅供参考,不构成投资建议。
| 季度 | 截止日 | 申报日 | 营收 | 营收同比 g | Δg | 推导方式 |
|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | 2026-11-02 | $5.14B | +1.4% | −6.1pp | 3M |
| 2026Q2 | 2026-06-30 | 2026-08-03 | $5.44B | +7.5% | −4.1pp | 3M |
| 2026Q1 | 2026-03-31 | 2026-05-01 | $5.2B | +11.6% | −4.3pp | 3M |
| 2025Q4 | 2025-12-31 | 2026-11-02 | $5.29B | +15.9% | −4.4pp | FY-9M |
| 2025Q3 | 2025-09-30 | 2026-11-02 | $5.07B | +20.3% | −2.5pp | 3M |
| 2025Q2 | 2025-06-30 | 2026-08-03 | $5.06B | +22.8% | +1.9pp | 3M |
| 2025Q1 | 2025-03-31 | 2026-05-01 | $4.66B | +20.9% | −1.5pp | 3M |
| 2024Q4 | 2024-12-31 | 2026-02-17 | $4.56B | +22.4% | +3.1pp | FY-9M |
口径:单季同比;Δg = 本季 g − 上季 g;按财季映射日历季度;申报日可见。† 不连续点(上年同季营收 ≤0 或 Δg 幅度超过 50pp)。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 季度 | 截止日 | 毛利 | 销货成本 | 毛利率 | 环比 | 同比 | Δ² |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $3.43B | $1.71B | 66.7% | −399bp | −321bp | −627bp |
| 2026Q2 | 2026-06-30 | $3.85B | $1.59B | 70.7% | +125bp | +305bp | +243bp |
| 季度 | 截止日 | 合同负债 | CL g | RPO | RPO g | 账单额 | 账单额 g | RPO 覆盖 |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $711M | +6.4% | 无数据 | 无数据 | $5.16B | +1.7% | 无数据 |
| 2026Q2 | 2026-06-30 | $691M | +4.4% |
| 季度 | 截止日 | OCF TTM | OCF g | CapEx TTM | CapEx g | FCF TTM | CapEx 密度 | SBC/FCF | SBC/Rev |
|---|---|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $4.23B | −8.5% | $903M | +12.6% | $3.33B | 4.3% | 9.4% | 1.5% |
| 2026Q2 | 2026-06-30 | $4.53B |
| 季度 | 截止日 | 存货 | 存货 g | 营收 g | 剪刀差 | DIO | DIO 同比 |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-09-30 | $3.32B | +13.6% | +1.4% | +12.1pp | 177.0 | +2.0 |
| 2026Q2 | 2026-06-30 | $3.24B | +13.1% | +7.5% | +5.5pp | 185.2 |
| 交易日 | 申报日 | 申报人 | 头衔 | 代码 | 股数 | 价格 | 金额 | 10b5-1 |
|---|---|---|---|---|---|---|---|---|
| 2026-08-25 |
口径:修正广度 =(近 30 日上调 − 下调)/(上调 + 下调),样本 < 3 不出;只展示衍生指标,不展示一致预期原值。 · 数据截至 2026-11-16 · 来源:Yahoo Finance / Nasdaq
未覆盖(期权覆盖为 S&P 500 期权持仓前 100 名每日、其余每周轮换)
口径:本股的警报事件历史(含基线);事件保留 90 天。
| 2026Q1 | 2026-03-31 | $3.61B | $1.59B | 69.5% | −14bp | +62bp | −112bp |
| 2025Q4 | 2025-12-31 | $3.68B | $1.61B | 69.6% | −33bp | +174bp | +64bp |
| 2025Q3 | 2025-09-30 | $3.54B | $1.52B | 69.9% | +228bp | +110bp | +262bp |
| 2025Q2 | 2025-06-30 | $3.42B | $1.64B | 67.7% | −119bp | −152bp | −169bp |
| 2025Q1 | 2025-03-31 | $3.21B | $1.45B | 68.8% | +98bp | +17bp | +154bp |
| 2024Q4 | 2024-12-31 | $3.1B | $1.47B | 67.9% | −97bp | −138bp | −142bp |
口径:GM = 毛利/营收;毛利缺失时用 营收−销货成本 推导;环比/同比为基点。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 无数据 |
| $5.45B |
| +7.2% |
| 无数据 |
| 2026Q1 | 2026-03-31 | $686M | +7.0% | 无数据 | 无数据 | $5.21B | +11.5% | 无数据 |
| 2025Q4 | 2025-12-31 | $682M | +7.4% | 无数据 | 无数据 | $5.3B | +15.8% | 无数据 |
| 2025Q3 | 2025-09-30 | $668M | +8.1% | 无数据 | 无数据 | $5.07B | +19.9% | 无数据 |
| 2025Q2 | 2025-06-30 | $662M | +10.5% | 无数据 | 无数据 | $5.08B | +23.2% | 无数据 |
| 2025Q1 | 2025-03-31 | $641M | +8.1% | 无数据 | 无数据 | $4.67B | +20.6% | 无数据 |
| 2024Q4 | 2024-12-31 | $635M | +10.1% | 无数据 | 无数据 | $4.58B | +21.9% | 无数据 |
口径:g = 同比;账单额 = 营收 + Δ合同负债(同口径);RPO 覆盖 = RPO / TTM 营收。跨口径(总额/仅流动)不比较。 合同负债口径: 总额 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| +5.7% |
| $904M |
| +13.0% |
| $3.63B |
| 4.3% |
| 8.8% |
| 1.5% |
| 2026Q1 | 2026-03-31 | $4.34B | +13.9% | $866M | +8.5% | $3.48B | 4.2% | 8.9% | 1.5% |
| 2025Q4 | 2025-12-31 | $4.53B | +32.0% | $876M | +10.9% | $3.66B | 4.4% | 8.2% | 1.5% |
| 2025Q3 | 2025-09-30 | $4.63B | +57.6% | $802M | +2.8% | $3.82B | 4.1% | 7.8% | 1.5% |
| 2025Q2 | 2025-06-30 | $4.29B | +62.8% | $800M | +1.1% | $3.49B | 4.3% | 8.2% | 1.5% |
| 2025Q1 | 2025-03-31 | $3.81B | +53.9% | $798M | +2.4% | $3.01B | 4.5% | 9.2% | 1.6% |
| 2024Q4 | 2024-12-31 | $3.44B | +37.2% | $790M | +11.1% | $2.65B | 4.7% | 10.1% | 1.6% |
口径:TTM = 近四个离散单季之和;FCF = OCF − CapEx;CapEx 密度 = CapEx/营收 TTM;FCF≤0 时 SBC/FCF 不计算。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| +25.7 |
| 2026Q1 | 2026-03-31 | $3.12B | +8.7% | +11.6% | −2.9pp | 178.9 | −1.2 |
| 2025Q4 | 2025-12-31 | $2.94B | +4.7% | +15.9% | −11.2pp | 167.0 | −7.9 |
| 2025Q3 | 2025-09-30 | $2.92B | +6.1% | +20.3% | −14.2pp | 175.0 | −16.5 |
| 2025Q2 | 2025-06-30 | $2.86B | +9.7% | +22.8% | −13.1pp | 159.5 | −27.9 |
| 2025Q1 | 2025-03-31 | $2.87B | +11.9% | +20.9% | −9.0pp | 180.1 | −13.2 |
| 2024Q4 | 2024-12-31 | $2.81B | +13.1% | +22.4% | −9.3pp | 174.9 | −22.7 |
口径:剪刀差 = 存货同比 − 营收同比(pp,正值=存货增速快于营收);DIO = 存货/销货成本 × 91.25 天。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 2026-08-26 |
| Morano Susan E |
| — |
| P |
| 2,040 |
| $49.22 |
| $100.41K |
| 2026-08-05 | 2026-08-07 | Habiger David C | — | P | 2,100 | $47.59 | $99.94K |
| 2026-08-04 | 2026-08-05 | Habiger David C | — | P | 140 | $48.59 | $6.8K |
| 2026-08-03 | 2026-08-05 | Habiger David C | — | P | 1,042 | $48.07 | $50.09K |
| 2026-08-03 | 2026-08-05 | Mahoney Michael F | Chairman, President & CEO | P | 186,240 | $48.33 | $9M |
| 2026-07-31 | 2026-08-03 | LUDWIG EDWARD J | — | P | 5,000 | $45.48 | $227.4K |
| 2026-05-20 | 2026-05-21 | Pegus Cheryl | — | P | 1,770 | $56.49 | $99.99K |
| 2026-05-20 | 2026-05-21 | LUDWIG EDWARD J | — | P | 3,580 | $56.68 | $202.91K |
| 2026-05-20 | 2026-05-21 | Habiger David C | — | P | 2,250 | $55.92 | $125.82K |
| 2026-05-19 | 2026-05-21 | Habiger David C | — | P | 2,200 | $56.95 | $125.29K |
| 2026-02-02 | 2026-02-03 | Mahoney Michael F | Chairman, President & CEO | S | 1,200 | $94.06 | $112.87K | ✓ |
| 2026-02-02 | 2026-02-03 | Mahoney Michael F | Chairman, President & CEO | S | 159,701 | $93.49 | $14.93M | ✓ |
| 2025-12-01 | 2025-12-02 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | S | 17,313 | $101.55 | $1.76M | ✓ |
| 2025-11-06 | 2025-11-06 | Zane Ellen M | — | S | 12,891 | $98.28 | $1.27M | ✓ |
| 2025-11-03 | 2025-11-04 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | S | 3,600 | $100.75 | $362.7K | ✓ |
| 2025-11-03 | 2025-11-04 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | S | 29,472 | $99.14 | $2.92M | ✓ |
| 2025-11-03 | 2025-11-04 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | S | 16,928 | $99.76 | $1.69M | ✓ |
| 2025-10-28 | 2025-10-28 | Zane Ellen M | — | S | 2,901 | $102.24 | $296.6K | ✓ |
| 2025-10-27 | 2025-10-28 | Zane Ellen M | — | S | 9,990 | $101.13 | $1.01M | ✓ |
| 2025-10-01 | 2025-10-01 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | S | 41,755 | $98.38 | $4.11M | ✓ |
| 2025-10-01 | 2025-10-01 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | S | 8,245 | $98.91 | $815.51K | ✓ |
| 2025-09-02 | 2025-09-03 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | S | 28,170 | $105.85 | $2.98M | ✓ |
| 2025-09-02 | 2025-09-03 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | S | 21,830 | $104.89 | $2.29M | ✓ |
| 2025-08-01 | 2025-08-04 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | S | 50,000 | $104.63 | $5.23M | ✓ |
| 2025-08-01 | 2025-08-04 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | S | 17,313 | $104.63 | $1.81M | ✓ |
| 2025-07-29 | 2025-07-30 | FUJIMORI YOSHIAKI | — | S | 2,901 | $106.99 | $310.38K |
| 2025-07-25 | 2025-07-28 | LUDWIG EDWARD J | — | S | 4,000 | $106.03 | $424.12K |
| 2025-07-01 | 2025-07-02 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | S | 50,000 | $106.97 | $5.35M | ✓ |
| 2025-06-04 | 2025-06-04 | Fitzgerald Joseph Michael | EVP & Group Pres, Cardiology | S | 56,372 | $102.88 | $5.8M | ✓ |
| 2025-06-02 | 2025-06-03 | Mahoney Michael F | Chairman, President & CEO | S | 74,522 | $104.05 | $7.75M | ✓ |
| 2025-06-02 | 2025-06-03 | Mahoney Michael F | Chairman, President & CEO | S | 89,921 | $103.39 | $9.3M | ✓ |
| 2025-05-29 | 2025-05-30 | LUDWIG EDWARD J | — | S | 4,000 | $104.59 | $418.36K |
| 2025-05-21 | 2025-05-22 | Brown Vance R | SVP, GC and Corp. Secretary | S | 4,826 | $106.42 | $513.58K | ✓ |
| 2025-05-05 | 2025-05-06 | Sorenson John Bradley | EVP, Global Operations | S | 4,572 | $104.54 | $477.96K | ✓ |
| 2025-05-01 | 2025-05-05 | Mahoney Michael F | Chairman, President & CEO | S | 73,161 | $102.92 | $7.53M | ✓ |
| 2025-05-01 | 2025-05-05 | Mahoney Michael F | Chairman, President & CEO | S | 91,282 | $102.13 | $9.32M | ✓ |
| 2025-05-01 | 2025-05-05 | Butcher Arthur C | EVP& Grp Pres, MedSurg & APAC | S | 17,314 | $102.06 | $1.77M | ✓ |
| 2025-04-21 | 2025-04-22 | Brown Vance R | SVP, GC and Corp. Secretary | S | 4,826 | $95.09 | $458.9K | ✓ |
| 2025-04-01 | 2025-04-02 | Mahoney Michael F | Chairman, President & CEO | S | 164,442 | $100.01 | $16.45M | ✓ |
| 2025-03-21 | 2025-03-24 | Brown Vance R | SVP, GC and Corp. Secretary | S | 4,826 | $100.85 | $486.7K | ✓ |
口径:Form 4/4A 公开市场买入(P)与卖出(S),申报人为董事或高管;汇总与集群为近 365 天,明细为最近 40 笔。 · 数据截至 2026-11-16 · 来源:SEC EDGAR Form 4
口径:SI 来自 FINRA(双周结算);SI% 分母 = SEC 封面总股本;借券费为 IBKR 报价(非全市场);卖空占比 = 当日卖空量/总成交量。 · 数据截至 SI 2026-10-30 · Reg SHO 2026-11-16 · 借券 2026-11-11 · 沿用上一版 · 来源:FINRA、IBKR、iBorrowDesk